Key result
Sequencing the novel FMDV Asia1 lineage identifies 13 crucial antigenic substitutions versus the existing vaccine strain.
Why the study?
A novel circulatory FMDV serotype Asia1 BD-18 (G-IX) lineage with unique mutations emerged in Bangladesh, requiring genomic characterization compared to existing vaccine strains.
The first complete genome sequence of the novel FMDV serotype Asia1 BD-18 (G-IX) lineage from Bangladesh reveals critical amino acid substitutions at antigenic sites, which may impact vaccine efficacy.
Answers are grounded in this paper and cite their sources.
Emerging Sindh-08 Asia1 circulation signals surveillance needs; leaves open vaccine and control strategy questions.
Foot-and-Mouth Disease (FMD) has been a major threat to livestock worldwide, and is caused by FMD Virus (FMDV) existing as seven serotypes (A, O, C, Asia1 and SAT 1-3), each having variability into topotypes, genetic lineages, sublineages, and strains. Three serotypes are circulating in Indian subcontinent with the widespread distribution of serotype O, whereas serotype A and Asia1 are restricted to certain geographical regions. During 2017-2018, the Sindh-08 lineages of Asia1 serotype was reported from Pakistan, however, in 2018, a novel circulatory foot-and-mouth disease virus serotype Asia1 BD-18 (G-IX) lineage containing a unique mutation has emerged in Bangladesh. The first complete genome of the Asia1/ASIA/G-IX novel lineage strain, isolated from Bangladesh, is reported here. Amino acid substitutions at critical antigenic sites of capsid were identified compared to genome of existing vaccine strain (IND/63/72), and contemporary FMDV serotype A isolate of Bangladesh.
No takes yet. Share an insight, caveat, or question.
Alam et al. (2019) studied Foot-and-Mouth Disease (n=1). FMDV Asia1/ASIA/G-IX (BD-18) lineage vs. Vaccine strain (IND/63/72) was evaluated on Complete genome sequence and amino acid substitutions. The complete genome of the novel FMDV Asia1/ASIA/G-IX (BD-18) lineage was sequenced, identifying 13 crucial amino acid substitutions at antigenic sites compared to the existing vaccine strain.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: